Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen J Demarest

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Biochemistry|April 11, 2013
Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell linesStephen J Demarest, Jennifer Gardner, Michelle C Vendel, et al.
Mabs|January 12, 2010
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaRJennifer S Michaelson, Stephen J Demarest, Brian Miller, et al.
Nature Communications|May 13, 2020
Computational stabilization of T cell receptors allows pairing with antibodies to form bispecificsKaren Froning, Jack Maguire, Arlene Sereno, et al.
Nature Communications|May 1, 2025
Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical studyAnja Koester, Derrick R Witcher, Mark Lee, et al.
Nature Biotechnology|January 28, 2014
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interfaceSteven M Lewis, Xiufeng Wu, Anna Pustilnik, et al.
The Journal of Biological Chemistry|December 3, 2010
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activityJianying Dong, Arlene Sereno, William B Snyder, et al.
The Journal of Biological Chemistry|February 13, 2009
Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivoAdam Doern, Xianjun Cao, Arlene Sereno, et al.
Mabs|March 12, 2011
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityJianying Dong, Arlene Sereno, Dikran Aivazian, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Biochemistry|April 11, 2013
Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell linesStephen J Demarest, Jennifer Gardner, Michelle C Vendel, et al.
Mabs|January 12, 2010
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaRJennifer S Michaelson, Stephen J Demarest, Brian Miller, et al.
Nature Communications|May 13, 2020
Computational stabilization of T cell receptors allows pairing with antibodies to form bispecificsKaren Froning, Jack Maguire, Arlene Sereno, et al.
Nature Communications|May 1, 2025
Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical studyAnja Koester, Derrick R Witcher, Mark Lee, et al.
Nature Biotechnology|January 28, 2014
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interfaceSteven M Lewis, Xiufeng Wu, Anna Pustilnik, et al.
The Journal of Biological Chemistry|December 3, 2010
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activityJianying Dong, Arlene Sereno, William B Snyder, et al.
The Journal of Biological Chemistry|February 13, 2009
Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivoAdam Doern, Xianjun Cao, Arlene Sereno, et al.
Mabs|March 12, 2011
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityJianying Dong, Arlene Sereno, Dikran Aivazian, et al.
Pageof 4